The global medical imaging reagents market size accounted for USD 18.10 billion in 2024, grew to USD 19.30 billion in 2025 and is predicted to surpass around USD 34.30 billion by 2034, representing a healthy CAGR of 6.60% between 2024 and 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Medical Imaging Reagents Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Medical Imaging Reagents Market, by Modality, 2024-2034
8.1.1 X-ray
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. CT Scan
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Ultrasound
8.1.3.1. Market Revenue and Forecast (2021-2034)
8.1.4. MRI Scan
8.1.4.1. Market Revenue and Forecast (2021-2034)
9.1. Medical Imaging Reagents Market, by Class, 2024-2034
9.1.1. Contrast Reagent
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Optical Reagent
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Nuclear Reagent
9.1.3.1. Market Revenue and Forecast (2021-2034)
10.1. Medical Imaging Reagents Market, by Application, 2024-2034
10.1.1. Neurological Disorder
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Cardiovascular Disorder
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Cancer
10.1.3.1. Market Revenue and Forecast (2021-2034)
10.1.4. Gastrointestinal Disorder
10.1.4.1. Market Revenue and Forecast (2021-2034)
10.1.5. Musculoskeletal Disorder
10.1.5.1. Market Revenue and Forecast (2021-2034)
10.1.6. Nephrological Disorder
10.1.6.1. Market Revenue and Forecast (2021-2034)
10.1.7. Others
10.1.7.1. Market Revenue and Forecast (2021-2034)
11.1. North America
11.1.1. Market Revenue and Forecast, by Modality (2021-2034)
11.1.2. Market Revenue and Forecast, by Class (2021-2034)
11.1.3. Market Revenue and Forecast, by Application (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Modality (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Class (2021-2034)
11.1.4.3. Market Revenue and Forecast, by Application (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Modality (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Class (2021-2034)
11.1.5.3. Market Revenue and Forecast, by Application (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Modality (2021-2034)
11.2.2. Market Revenue and Forecast, by Class (2021-2034)
11.2.3. Market Revenue and Forecast, by Application (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Modality (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Class (2021-2034)
11.2.4.3. Market Revenue and Forecast, by Application (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Modality (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Class (2021-2034)
11.2.5.3. Market Revenue and Forecast, by Application (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Modality (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Class (2021-2034)
11.2.6.3. Market Revenue and Forecast, by Application (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Modality (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Class (2021-2034)
11.2.7.3. Market Revenue and Forecast, by Application (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Modality (2021-2034)
11.3.2. Market Revenue and Forecast, by Class (2021-2034)
11.3.3. Market Revenue and Forecast, by Application (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Modality (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Class (2021-2034)
11.3.4.3. Market Revenue and Forecast, by Application (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Modality (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Class (2021-2034)
11.3.5.3. Market Revenue and Forecast, by Application (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Modality (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Class (2021-2034)
11.3.6.3. Market Revenue and Forecast, by Application (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Modality (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Class (2021-2034)
11.3.7.3. Market Revenue and Forecast, by Application (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Modality (2021-2034)
11.4.2. Market Revenue and Forecast, by Class (2021-2034)
11.4.3. Market Revenue and Forecast, by Application (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Modality (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Class (2021-2034)
11.4.4.3. Market Revenue and Forecast, by Application (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Modality (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Class (2021-2034)
11.4.5.3. Market Revenue and Forecast, by Application (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Modality (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Class (2021-2034)
11.4.6.3. Market Revenue and Forecast, by Application (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Modality (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Class (2021-2034)
11.4.7.3. Market Revenue and Forecast, by Application (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Modality (2021-2034)
11.5.2. Market Revenue and Forecast, by Class (2021-2034)
11.5.3. Market Revenue and Forecast, by Application (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Modality (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Class (2021-2034)
11.5.4.3. Market Revenue and Forecast, by Application (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Modality (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Class (2021-2034)
11.5.5.3. Market Revenue and Forecast, by Application (2021-2034)
12.1. Abbott Bracco Spa
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Lantheus Holdings, Inc
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. General Electric Company
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Siemens AG
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Bayer AG
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. CMC Contrast AB
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Thermo Fisher Scientific Inc
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Merck & Co., Inc
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Shimadzu Corporation
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Koninklijke Philips N.V.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample